Biotech Catalysts This Week: 1 FDA Decision, 1 Trial Completion and 8 New Financings (Oct 11-18, 2026)

· 5 min read

This week centers on IRD’s PDUFA date of 2026-10-17 for Phentolamine Ophthalmic Solution 0.75%, alongside an estimated primary completion date for BMY’s LIBREXIA-STROKE trial. Last week brought three new company-guided timelines from EPRX, OSTX and BNTC, three trial status changes including two for ARWR, and twelve key SEC filings, with no delays or discontinuations recorded.

At a glance: this week 1 FDA decision date, 1 Phase 2 or 3 trial reaching primary completion and 8 new financing filings. Last week: 3 new timelines announced and 12 key SEC filings.

🔄 What Changed Last Week

New timelines announced in press releases:

  • EPRX, RESOLVE: December 2026. “The interim data from the Phase 2b portion of the RESOLVE trial are expected in December 2026.” SEC filing
  • OSTX, OS Therapies MHRA Conditional Marketing Authorization Application (CMAA): early in fourth quarter of 2026. “OS Therapies is pursuing MHRA Conditional Marketing Authorization Application (CMAA) under Project Orbis via its Innovative Licensing and Access Pathway (ILAP), with a submission…” SEC filing
  • BNTC, BB-301: mid-2027. “The BB-301 pivotal trial remains on track to begin in mid-2027” SEC filing

Trial status changes on ClinicalTrials.gov:

  • VNDA: Phase 3 trial marked completed (2026-10-10). Evaluating the Effects of Tasimelteon vs. Placebo in Delayed Sleep-Wake Phase Disorder (DSWPD) Registry
  • ARWR: Phase 3 trial marked completed (2026-10-10). Study of Plozasiran in Adults With Severe Hypertriglyceridemia Registry
  • ARWR: Phase 3 trial marked completed (2026-10-09). Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia Registry

📄 Key SEC Filings Last Week

Filings that can move a stock, each summarized from the filing itself; financing filings are under Dilution Watch below:

  • ARGX, 2026-10-08 (clinical trial): Phase 2 study of FB102 in celiac disease met its primary endpoint, change from baseline in villus height-to-crypt depth ratio at day 78 versus placebo (p=0.0176). The company plans to advance FB102 into Phase 3 development. SEC filing
  • ADXN, 2026-10-08 (clinical trial): Spin-out Neurosterix completed Phase 1 studies of NTX-253, an oral M4 PAM for schizophrenia, and plans to advance it into Phase 2 patient studies. Addex holds a 20% equity interest in Neurosterix. SEC filing
  • KAPA, 2026-10-06 (clinical trial): Reported interim Phase 2 data for ENV-105 (carotuximab) plus apalutamide in metastatic castration-resistant prostate cancer, with median progression-free survival of 17.7 months versus 2 months for apalutamide alone (P=0.0008). SEC filing
  • AVBP, 2026-10-06 (clinical trial): Phase 3 FURVENT trial of firmonertinib in first-line EGFR exon 20 insertion NSCLC missed its primary PFS endpoint by BICR: median PFS 11.0 months at 240mg and 8.4 months at 160mg vs 9.5 months control (p=0.0654 for 240mg). Safety was consistent with prior studies. SEC filing
  • PCVX, 2026-10-05 (clinical trial): Reported positive topline data from the Phase 3 OPUS-1 adult trial of VAX-31. All 28 serotypes shared with PCV20 and/or PCV21 met noninferiority at the >0.667 threshold, and VAX-31 was well tolerated. OPUS-2 and OPUS-3 results are expected in first half 2027, with BLA submission planned for first half 2028. SEC filing
  • VALN, 2026-10-08 (regulatory): Valneva said the UK MHRA revoked the UK marketing authorization for IXCHIQ after a further benefit-risk review by the CHM, with no new safety signal. Valneva disagrees but will not appeal, citing immaterial financial impact. EU, Canada and Brazil licenses are unaffected. SEC filing
  • CATX, 2026-10-08 (regulatory): FDA granted Fast Track Designation for PSV359, an FAP-targeted alpha-particle therapy, for adult patients with locally advanced unresectable and/or metastatic FAP-positive solitary fibrous tumors. The drug is in an ongoing Phase 1/2a study for advanced FAP-positive solid tumors. SEC filing
  • LPCN, 2026-10-07 (regulatory): Health Canada approved TLANDO (testosterone undecanoate) capsules for testosterone replacement therapy in adult males with male hypogonadism. Licensing partner Verity Pharma plans a Canadian launch by the end of 2026. SEC filing
  • BGMS, 2026-10-09 (deal): BGMS seeks stockholder approval for a share exchange with Future NRG Sdn. Bhd. under a June 4, 2026 agreement with a $2,000,000,000 aggregate consideration value, issuing shares to Selling Shareholders who would own over 99.0% of Parent. SEC filing
  • CVKD, 2026-10-07 (deal): Cadrenal’s board authorized a formal strategic process to evaluate options to maximize portfolio value, including licensing, asset sales, partnerships or business combinations. The company retained Tungsten Advisors as exclusive advisor and set no deadline; there is no assurance of any transaction. SEC filing
  • RGEN, 2026-10-06 (deal): Repligen completed its acquisition of BioLife Solutions. BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock per share, with cash in lieu of fractional shares. SEC filing
  • TCRT, 2026-10-09 (listing): Received a Nasdaq delisting notice on Oct 5, 2026 for not meeting the $2,500,000 minimum stockholders’ equity rule, and plans to request a hearing before the Nasdaq Hearings Panel. It is working with a financial advisor on strategic alternatives, with no assurance of compliance. SEC filing

💊 FDA Decisions (PDUFA Dates)

Date Ticker Drug Indication Type
2026-10-17 IRD Phentolamine Ophthalmic Solution 0.75% presbyopia sNDA

🧪 Phase 2 and 3 Trials Reaching Primary Completion

Estimated primary completion dates from ClinicalTrials.gov: the last patient reaches the main endpoint. Topline results usually follow weeks or months later.

  • BMY, 2026-10-15 (Phase 3): A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE Registry

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • ATOS: Phase 2 primary completion in 21 days, score 88/100
  • VSTM: Data readout guided for October 2026, window closes in 20 days, score 68/100
  • TLSA: Data readout guided for October, window closes in 20 days, score 67/100

💸 Dilution Watch: New Financing Filings

  • QUCY: ATM program up to $100M (424B5, 2026-10-09) EDGAR
  • MGRX: ATM program (424B5, 2026-10-09) EDGAR
  • BIAF: ATM program (424B5, 2026-10-09) EDGAR
  • BIAF: registered direct offering (424B5, 2026-10-09) EDGAR
  • BIAF: private placement (8-K, 2026-10-09) EDGAR
  • FBLG: private placement (8-K, 2026-10-08) EDGAR
  • ICU: private placement (8-K, 2026-10-05) EDGAR
  • IMNM: private placement (8-K, 2026-10-05) EDGAR

Full Dilution Watch table →

📉 Downside Radar: Trading Far Below a Recent Offering

Of biotech stocks 25% or more below their close on the day of a recent offering, 76% were lower 60 trading days later, median -29% (any biotech on a random day: 53% lower, median -2%). On the radar now:

  • DCOY: $1.47, 62% below $3.85, its close on the day of its Sep 23 private placement (new this week)
  • GRML: $5.17, 56% below $11.85, its close on the day of its Sep 28 registered direct offering (new this week)
  • LEXX: $3.32, 50% below $6.60, its close on the day of its Sep 9 private placement (new this week)
  • JUNS: $2.85, 50% below $5.66, its close on the day of its Aug 24 private placement (new this week)
  • AMLX: $28.14, 29% below $39.66, its close on the day of its Aug 20 underwritten offering (new this week)

Full Downside Radar and how it was tested →

📈 Last Week’s Biggest Gainers

  • APUS +55.34% (volume 13.2x average)
  • ZYBT +50.45% (volume 5.0x average)
  • PCRX +44.40% (volume 28.0x average)
  • PDSB +35.29% (volume 0.7x average)
  • CPHI +32.58% (volume 10.9x average)

Earlier weekly catalyst recaps →

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.